Charité - Universitätsmedizin Berlin Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany.
Tib-Molbiol, Berlin, Germany.
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur.
We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available.
Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology.
The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive - Global (EVAg), a European Union infrastructure project.
The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.
新出现的新型冠状病毒(2019-nCoV)的持续爆发对公共卫生实验室构成了挑战,因为病毒分离物不可用,而越来越多的证据表明,疫情的范围比最初想象的要广泛,而且国际旅行者已经出现了传播。
我们旨在开发和部署强大的诊断方法,以便在没有病毒材料的情况下在公共卫生实验室环境中使用。
在这里,我们提出了一种针对 2019-nCoV 的经过验证的诊断工作流程,其设计依赖于 2019-nCoV 与 SARS 冠状病毒的密切遗传关系,利用合成核酸技术。
该工作流程可靠地检测到 2019-nCoV,并进一步区分 2019-nCoV 和 SARS-CoV。通过学术和公共实验室之间的协调,我们基于包含人类呼吸道病毒全谱的 297 份原始临床标本证实了检测方法的特异性。通过欧盟基础设施项目欧洲病毒档案-全球(EVAg)提供对照材料。
本研究展示了通过国家和欧洲研究网络中的学术和公共实验室之间的协调实现的巨大响应能力。